CAS 112522-64-2|CI-994
| Common Name | CI-994 | ||
|---|---|---|---|
| CAS Number | 112522-64-2 | Molecular Weight | 269.298 |
| Density | 1.3±0.1 g/cm3 | Boiling Point | 450.6±30.0 °C at 760 mmHg |
| Molecular Formula | C15H15N3O2 | Melting Point | 242 °C(dec.) |
| MSDS | ChineseUSA | Flash Point | 226.3±24.6 °C |
| Symbol | GHS07 | Signal Word | Warning |
Names
| Name | 4-acetamido-N-(2-aminophenyl)benzamide |
|---|---|
| Synonym | More Synonyms |
CI-994 BiologicalActivity
| Description | CI-994 (Tacedinaline) is an inhibitor of the histone deacetylase (HDAC) with IC50s of 0.9, 0.9, 1.2 μM for recombinant HDAC 1, 2 and 3 respectively. |
|---|---|
| Related Catalog | Research Areas >>Cancer |
| Target | HD1:0.9 μM (IC50) HD2:0.9 μM (IC50) HD3:1.2 μM (IC50) |
| In Vitro | CI-994 (N-acetyldinaline) is a novel oral compound with a wide spectrum of antitumor activity in preclinical models. The mechanism of action may involve inhibition of histone deacetylation and cell cycle arrest. CI-994 is combined with antineoplastic agents commonly used in non-small cell lung cancer cell line management, a marked synergism of action (R=1.8, R=1.5) is observed between CI-994 (40 μM) and gemcitabine (0.01 μM) at 48 and 72 h of treatment[2].CI-994 inhibits mitogen-stimulated blood lymphocyte proliferation with an IC50 value of 3 μM[4]. |
| In Vivo | CI-994 has activity against 8/8 solid tumors tested: pancreatic ductal adenocarcinoma #02 (4.7); pancreatic adenocarcinoma #03 (3.0; 1/6 cures); colon adenocarcinoma #38 (1.6); colon adenocarcinoma #51/A (1.1); mammary adenocarcinoma #25 (1.7); mammary adenocarcinoma #17/ADR (0.5); Dunning osteogenic sarcoma (4.0); and the human prostate carcinoma LNCaP (1.2). CI-994 is the acetylated metabolite of dinaline and has the same spectrum of activity in vivo as dinaline. It also behaves similarly in schedule comparison/toxicity trials[3]. CI-994 can effect lymphoid tissue in rats within 1 day of a single oral dose, that effects are generally reversible within 7 days[4]. |
| Animal Admin | Rats: To characterize the effects of CI-994 on lymphoid tissue, male rats are administered single oral doses at 0 (vehicle control), 10, 23, and 45 mg/kg and killed up to 7 days after dosing for evaluation of white blood cell differentials, bone marrow differentials, lymphoid tissue weights, and selected histopathology of lymphoid tissue[4]. |
| References | [1]. Moradei OM, et al. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem. 2007 Nov 15;50(23):5543-6. [2]. Loprevite M, etal. In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines. Oncol Res. 2005;15(1):39-48. [3]. LoRusso PM, et al. Preclinical antitumor activity of CI-994. Invest New Drugs. 1996;14(4):349-56. [4]. Graziano MJ, et al. Immunotoxicity of the anticancer drug CI-994 in rats: effects on lymphoid tissue. Arch Toxicol. 1999 Apr-May;73(3):168-74. |
Chemical & Physical Properties
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 450.6±30.0 °C at 760 mmHg |
| Melting Point | 242 °C(dec.) |
| Molecular Formula | C15H15N3O2 |
| Molecular Weight | 269.298 |
| Flash Point | 226.3±24.6 °C |
| Exact Mass | 269.116425 |
| PSA | 84.22000 |
| LogP | 0.96 |
| Vapour Pressure | 0.0±1.1 mmHg at 25°C |
| Index of Refraction | 1.707 |
| InChIKey | VAZAPHZUAVEOMC-UHFFFAOYSA-N |
| SMILES | CC(=O)Nc1ccc(C(=O)Nc2ccccc2N)cc1 |
Safety Information
| Symbol | GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H319 |
| Precautionary Statements | P305 + P351 + P338 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
| Hazard Codes | Xi |
| Risk Phrases | 36 |
| Safety Phrases | 26 |
| RIDADR | NONH for all modes of transport |
| RTECS | CU8702023 |
| HS Code | 2924299090 |
Customs
| HS Code | 2924299090 |
|---|---|
| Summary | 2924299090. other cyclic amides (including cyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |
Articles25
More Articles| Role of a small molecular weight phosphoprotein in the mechanism of action of CI-994 (N-acetyldinaline). Int. J. Cancer 62(5) , 636-42, (1995) The mechanism of action of the novel anti-cancer compound CI-994 was studied in C26 murine colon tumor and HCT-8 human colon adenocarcinoma cells. Treatment of either cell line resulted in the specifi... | |
| Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors. Cancer Invest. 22(6) , 886-96, (2004) To determine maximum tolerated dose of CI-994, a novel oral histone deacetylase inhibitor, in combination with carboplatin and paclitaxel in patients with advanced solid tumors.Patients with advanced ... | |
| Cytotoxic chemotherapy regimens that increase dose per cycle (dose intensity) by extending daily dosing from 5 consecutive days to 28 consecutive days and beyond. Clin. Cancer Res. 6(6) , 2474-81, (2000) Dose intensity, defined as dose administered per unit time, has emerged as a potentially important measurement of anticancer drug exposure and determinant of efficacy. There are several strategies for... |
Synonyms
| Tacedinaline |
| 4-Acetamido-N-(2-aminophenyl)benzamide |
| 4-(Acetylamino)-N-(2-aminophenyl)benzamide |
| Goe 5549 |
| N-acetyldinaline |
| Acetyldinaline |
| Tacedinalina |
| Benzamide, 4-(acetylamino)-N-(2-aminophenyl)- |
| CI994 |
| CI-994 |
